New from NCI |
NCI-COG Pediatric MATCH Trial Launches |
| | The nationwide precision medicine trial will enroll children and adolescents with advanced cancer that hasn’t responded to standard therapy. Patients whose tumors have certain genetic changes will be treated with drugs that are designed to target those changes. |
Cooling Cap to Reduce Hair Loss Cleared for Wider Use |
| | The Food and Drug Administration (FDA) has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy—for use by patients with any type of solid tumor. |
Follow-Up Medical Care |
| | All cancer survivors should have follow-up care, which means seeing a health care provider for regular medical checkups once you have finished treatment. Visit our updated page to learn about follow-up care plans, tips for talking with your doctor, and more. |
Two-Drug Combination Approved for Lung Cancer with Changes in the BRAF Gene
FDA approved the combination of dabrafenib and trametinib to treat patients with metastatic non-small cell lung cancer that has a change in the BRAF gene called the V600E mutation. |
Drug Information Updates |
Blinatumomab Use in Leukemia
We’ve updated our summary on blinatumomab to reflect FDA’s recently expanded approval for use of the drug in patients with acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome positive. The previous approval was limited to patients with ALL whose tumor cells did not have this genetic alteration. |
Dabrafenib for Lung Cancer
We’ve updated our drug information summary on dabrafenib, which was recently approved by FDA to be used with trametinib to treat non-small cell lung cancer that has a certain mutation in the BRAF gene. |
Trametinib for Lung Cancer
We’ve updated our drug information summary on trametinib, which was recently approved by FDA to be used with dabrafenib to treat non-small cell lung cancer that has a certain mutation in the BRAF gene. |
No hay comentarios:
Publicar un comentario